Sanjivani Paranteral Limited reported a 32.6% year-on-year increase in standalone net profit to ₹229.54 lakh for the quarter ended June 30, 2026. Revenue from operations rose 8.7% to ₹1,945.84 lakh, reflecting steady demand in the pharmaceutical segment.

The Mumbai-based manufacturer also posted consolidated net profit attributable to owners of ₹241.28 lakh, up 39.1% from ₹173.06 lakh in the same period last year. Consolidated revenue from operations expanded 33.2% to ₹2,383.92 lakh.

Financial Performance

The company’s earnings per share (EPS) increased to ₹1.87 from ₹1.46 in Q1FY25. Profit before tax stood at ₹306.05 lakh, compared to ₹230.06 lakh in the prior year quarter.

Consolidated figures showed stronger top-line momentum, with revenue reaching ₹2,383.92 lakh against ₹1,789.22 lakh in Q1FY25. Other income contributed ₹15.08 lakh to total revenue.

What the Numbers Show

A notable divergence exists between standalone and consolidated performance. While standalone revenue grew modestly at 8.7%, consolidated revenue surged 33.2%. This suggests that the subsidiary, SPL Infusion Pvt. Ltd., contributed significantly to the group’s top-line expansion during the quarter.

Corporate Actions

The Board of Directors approved the unaudited financial results along with the limited review report from statutory auditors R.B. Gohil & Co. The board also approved the Annual Report and Director’s Report for FY26.

Key corporate developments include:

• Notice convening the 32nd Annual General Meeting (AGM) on September 16, 2026, via video conferencing or other audio-visual means.
• Closure of register of members and share transfer books from September 10 to September 16, 2026.
• Appointment of HD & Associates as scrutinizer for remote e-voting.

The company received no investor complaints during the quarter. Statutory auditors expressed an unmodified opinion on the standalone results.

Sanjivani Paranteral Limited has initiated a postal ballot to seek shareholder approval for the preferential allotment of up to 5,00,000 fully convertible warrants to its promoter, Ashwani Khemka, aggregating ₹7,36,95,000. The Board of Directors sanctioned the deal on July 23, 2026, at an issue price of ₹147.39 per warrant. This capital raise aims to strengthen the company’s financial position through promoter backing, with the warrants convertible into equity shares within 18 months. The move also seeks approval for material related-party transactions up to ₹10 crore with subsidiary SPL Infusion Private Limited for FY26-27.

The remote e-voting period commenced on July 24, 2026, and concludes on August 22, 2026. Shareholders holding shares as on the cut-off date of July 17, 2026, are eligible to vote. The results will be announced by August 24, 2026. The issuance is structured as a related-party deal requiring a special resolution under Section 42 of the Companies Act, 2013, and Regulation 160 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The pricing was determined in accordance with Chapter V of the SEBI ICDR Regulations, based on market conditions as of the 'Relevant Date,' July 23, 2026.

Deal Structure and Pricing

The warrants will convert into fully paid-up equity shares with a face value of ₹10 each, at the option of the warrant holder, in one or more tranches. If any warrants remain unconverted after 18 months from the date of allotment, they will lapse, and the subscription amount paid by the holder will be forfeited to the company. The proposed allotment details are as follows:

Impact on Shareholding Pattern

Upon conversion, the promoter’s shareholding in Sanjivani Paranteral Limited is expected to increase. Currently, Ashwani Khemka holds 36,70,117 equity shares, representing a 29.88% stake. Post-conversion, his holding is projected to rise to 41,70,117 shares, increasing his stake to 32.62%. This consolidation reflects the promoter’s confidence in the company’s future prospects. The post-issue shareholding structure on a fully diluted basis is detailed below:

Related-Party Transactions

The Board also approved material related-party transactions between the company and its subsidiary, SPL Infusion Private Limited, pursuant to Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholders are seeking an ordinary resolution to approve transactions including loans, guarantees, and purchase/sale of goods/services, not exceeding ₹10 crore during FY26-27. These transactions are intended to support the working capital requirements and business expansion of the subsidiary. The Audit Committee has reviewed the proposal, and the Board recommends it as being in the ordinary course of business and at arm's length.

Regulatory Approvals and Next Steps

The disclosure was submitted to BSE Limited under Regulation 30 of the SEBI Listing Regulations, signed by Company Secretary Ravikumar Venkatramalu Bogham on July 23, 2026. The company has engaged MUFG Intime India Private Limited to provide the remote e-voting facility. A practicing Company Secretary's certificate from HD & Associates confirms compliance with SEBI ICDR Regulations. The proceeds from the warrant issue, if converted, will be utilized for future expansion and growth by March 31, 2028, with interim funds deposited in scheduled commercial banks.